l2 pp7 vlps Search Results


90
Agilvax Inc pp7/ms2 bacteriophage vlps
Preclinical studies showing reactivity of HPV vaccines to cutaneous types/challenge.
Pp7/Ms2 Bacteriophage Vlps, supplied by Agilvax Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/l2+pp7+vlps/pp7+ms2+bacteriophage+vlps/pmc05942179-22-0-20
Average 90 stars, based on 1 article reviews
pp7/ms2 bacteriophage vlps - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
Agilvax Inc hpv5
Preclinical studies showing reactivity of HPV vaccines to cutaneous types/challenge.
Hpv5, supplied by Agilvax Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/l2+pp7+vlps/hpv5/pmc05942179-22-13-20
Average 90 stars, based on 1 article reviews
hpv5 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

Image Search Results


Preclinical studies showing reactivity of HPV vaccines to cutaneous types/challenge.

Journal: Frontiers in Microbiology

Article Title: Cutaneous Papillomaviruses and Non-melanoma Skin Cancer: Causal Agents or Innocent Bystanders?

doi: 10.3389/fmicb.2018.00874

Figure Lengend Snippet: Preclinical studies showing reactivity of HPV vaccines to cutaneous types/challenge.

Article Snippet: PP7/MS2 bacteriophage VLPs , HPV16 L2(20–29), (17–31), (14–40) and (14–65) , ND , HPV5 , Being developed by the company Agilvax with DMID/NIAID/NIH support ( ). , .

Techniques: Vaccines, In Vitro, Bioprocessing, Produced, Clinical Proteomics

Preclinical studies showing reactivity of HPV vaccines to cutaneous types/challenge.

Journal: Frontiers in Microbiology

Article Title: Cutaneous Papillomaviruses and Non-melanoma Skin Cancer: Causal Agents or Innocent Bystanders?

doi: 10.3389/fmicb.2018.00874

Figure Lengend Snippet: Preclinical studies showing reactivity of HPV vaccines to cutaneous types/challenge.

Article Snippet: PP7/MS2 bacteriophage VLPs , HPV16 L2(20–29), (17–31), (14–40) and (14–65) , ND , HPV5 , Being developed by the company Agilvax with DMID/NIAID/NIH support ( ). , .

Techniques: In Vitro, Produced